Progress and future of in vitro models to study translocation of nanoparticles
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The increasing use of nanoparticles in products likely results in increased exposure of both workers and consumers. Because of their small size, there are concerns that nanoparticles unintentionally cross the barriers of the human body. Several in vivo rodent studies show that, dependent on the exposure route, time, and concentration, and their characteristics, nanoparticles can cross the lung, gut, skin, and placental barrier. This review aims to evaluate the performance of in vitro models that mimic the barriers of the human body, with a focus on the lung, gut, skin, and placental barrier. For these barriers, in vitro models of varying complexity are available, ranging from single-cell-type monolayer to multi-cell (3D) models. Only a few studies are available that allow comparison of the in vitro translocation to in vivo data. This situation could change since the availability of analytical detection techniques is no longer a limiting factor for this comparison. We conclude that to further develop in vitro models to be used in risk assessment, the current strategy to improve the models to more closely mimic the human situation by using co-cultures of different cell types and microfluidic approaches to better control the tissue microenvironments are essential. At the current state of the art, the in vitro models do not yet allow prediction of absolute transfer rates but they do support the definition of relative transfer rates and can thus help to reduce animal testing by setting priorities for subsequent in vivo testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The origins and the future of microfluidics
Whitesides, G. M. (2006) · Nature · doi:10.1038/nature05058 · Cited by 9,687
A standardised static in vitro digestion method suitable for food – an international consensus
Minekus, M., Alminger, M., Alvito, P., Ballance, S., Bohn, T., Bourlieu, C., Carrière, F., Boutrou, R., Corredig, M., Dupont, D., et al. (2014) · Food Funct. · doi:10.1039/c3fo60702j · Cited by 5,824 · cited 1×
“Human digestion models can first be simple and static, and mimic only gastric or small intestinal conditions, in which materials are incubated with simulated gastric fluids, simulated small intestinal fluids or buffers at static pH values (Mwilu et al. 2013; Minekus et al. 2014).”
BackgroundReconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250 · cited 4×
“…2014; Huh et al. 2012; Moraes et al. 2012; van der Meer and van den Berg 2012), which can be seen as hybrid devices combining cells and microfabricated structures aiming to recapitulate the dynamic physical, cellular, and functional features of human tissues (Ardavin et al. 2001; Huh et al. 2010.”
BackgroundInfluentialTranslocation of inhaled ultrafine particles to the brain
Oberdörster, G., Sharp, Z., Atudorei, V., Elder, A., Gelein, R., Kreyling, W., & Cox, C. (2004) · Inhalation Toxicology · doi:10.1080/08958370490439597 · Cited by 2,606
Filipe, V., Hawe, A., & Jiskoot, W. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0073-2 · Cited by 1,885
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus
Lai, S. K., O'Hanlon, D. E., Harrold, S., Man, S. T., Wang, Y.-Y., Cone, R., & Hanes, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608611104 · Cited by 1,050 · cited 1×
“This mucus layer might be a very important barrier for nanoparticles in vivo because of electrostatic repulsion (for negatively charged nanoparticles) and mucus entrapment (for positively charged nanoparticles) (Husain et al. 2001; Lai et al. 2007; Norris et al. 1998; Szentkuti and Lorenz 1995).”
BackgroundNanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency
Jani, P., Halbert, G. W., Langridge, J., & Florence, A. T. (1990) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1990.tb07033.x · Cited by 920 · cited 3×
“The estimated oral bioavailability of 50-nm polystyrene nanoparticles varied between studies from 0.2 to 1.7 % (Walczak et al., submitted) to 6.6 % (Jani et al. 1990).”
BackgroundInfluentialGut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation
Kim, H. J., & Ingber, D. E. (2013) · Integrative Biology · doi:10.1039/c3ib40126j · Cited by 750 · cited 3×
“Over the years, examples of organ-on-a-chip models in the literature have diversified and, for instance, include gut (Kim and Ingber 2013), lung (Huh et al. 2007, 2010; Nalayanda et al. 2010), or even blood–brain barriers (Griep et al. 2013; Huh et al. 2013; Wolff et al. 2015).”
BackgroundDeposition and biokinetics of inhaled nanoparticles
Geiser, M., & Kreyling, W. G. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-2 · Cited by 747 · cited 1×
“Deeper in the airways, the clearance is slower, given the increased pathway length and decreased mucous velocity (Geiser and Kreyling 2010).”
BackgroundMicrofabrication of human organs-on-chips
Huh, D., Kim, H. J., Fraser, J. P., Shea, D. E., Khan, M., Bahinski, A., Hamilton, G. A., & Ingber, D. E. (2013) · Nature Protocols · doi:10.1038/nprot.2013.137 · Cited by 712 · cited 2×
“Over the years, examples of organ-on-a-chip models in the literature have diversified and, for instance, include gut (Kim and Ingber 2013), lung (Huh et al. 2007, 2010; Nalayanda et al. 2010), or even blood–brain barriers (Griep et al. 2013; Huh et al. 2013; Wolff et al. 2015).”
BackgroundInfluence of particle size on regional lung deposition – What evidence is there?
Carvalho, T. C., Peters, J. I., & Williams III, R. O. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.040 · Cited by 614
VanDussen, K. L., Marinshaw, J. M., Shaikh, N., Miyoshi, H., Moon, C., Tarr, P. I., Ciorba, M. A., & Stappenbeck, T. S. (2015) · Gut · doi:10.1136/gutjnl-2013-306651 · Cited by 525
Wagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476 · cited 2×
“2013; Schimek et al. 2013; Wagner et al. 2013).”
BackgroundGeraets, L., Oomen, A. G., Schroeter, J. D., Coleman, V. A., & Cassee, F. R. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs113 · Cited by 176 · cited 4×
“For cerium dioxide, the uptake rate in vivo is very low, and only about 10 % of the inhaled cerium dioxide was detected in the lungs (Geraets et al. 2012), while 80 % of the particles was internalized in cells in vitro (Raemy et al.”
BackgroundInfluentialApplication of short-term inhalation studies to assess the inhalation toxicity of nanomaterials
Landsiedel, R., Ma-Hock, L., Hofmann, T., Wiemann, M., Strauss, V., Treumann, S., Wohlleben, W., Gröters, S., Wiench, K., & van Ravenzwaay, B. (2014) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-11-16 · Cited by 169 · cited 5×
“Nanoparticles, especially those that dissolve readily such as ZnO, may be able to translocate the mucus layer and reach the epithelial cells and thus cause local damage (Frieke Kuper et al. 2015; Landsiedel et al. 2014a; Vandebriel and De Jong 2012).”
BackgroundInfluentialSkin barrier in atopic dermatitis
Kezic, S. (2014) · Frontiers in Bioscience · doi:10.2741/4225 · Cited by 115 · cited 1×
“For instance, one of the main features of a common inflammatory skin disease, atopic dermatitis (AD), is a damaged skin barrier (Kezic et al. 2014).”
BackgroundLi, H., van Ravenzwaay, B., Rietjens, I. M. C. M., & Louisse, J. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1074-9 · Cited by 99
Self-citationHillery, A. M., & Florence, A. T. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)04353-5 · Cited by 81 · cited 4×
“…calculated as a sum of the small- and large intestinal walls), were lower than the ones reported by others for 60-nm nanoparticles (between 1.5 and 10 %, depending on the type (i.e. surface chemistry) of polystyrene nanoparticles used) (Hillery and Florence 1996; Hillery et al. 1994).”
BackgroundInfluential
Cited by
Bouwmeester, H., Hollman, P. C. H., & Peters, R. J. B. (2015) · Environmental Science & Technology · doi:10.1021/acs.est.5b01090 · Cited by 1,180
Self-citationNanoparticles for oral delivery: Design, evaluation and state-of-the-art
Date, A. A., Hanes, J., & Ensign, L. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.016 · Cited by 539
De Matteis, V. (2017) · Toxics · doi:10.3390/toxics5040029 · Cited by 362
Miao, T., Wang, J., Zeng, Y., Liu, G., & Chen, X. (2018) · Advanced Science · doi:10.1002/advs.201700513 · Cited by 362
Upadhyay, S., & Palmberg, L. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy053 · Cited by 292
Metadata
- Authors
- Braakhuis, H. M., Kloet, S. K., Kezic, S., Kuper, F., Park, M. V. D. Z., Bellmann, S., van der Zande, M., Le Gac, S., Krystek, P., Peters, R. J. B., Rietjens, I. M. C. M., & Bouwmeester, H.
- Venue
- Archives of Toxicology
- Published
- 2015-05-15
- Volume
- 89
- Issue
- 9
- Pages
- 1469-1495
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W1873573341
- Cited by
- 142
- References
- 18
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.